SER vs NRXP vs INMB vs SAVA

For growth investors, INmune Bio, Inc.

(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus -98. 2% for Serina Therapeutics, Inc. (SER). Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cassava Sciences, Inc.

(SAVA) delivered a total return of -64. 6%, compared to -99. 0% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus SER's -98. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Serina Therapeutics, Inc.

(SER) is the lower-risk stock at 1. 14β versus INmune Bio, Inc. 's 2. 43β — meaning INMB is approximately 114% more volatile than SER relative to the S&P 500. On balance sheet safety, INmune Bio, Inc. (INMB) carries a lower debt/equity ratio of 4% versus 53% for Serina Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INmune Bio, Inc.

(INMB) is pulling ahead at 257. 1% versus -98. 2% for Serina Therapeutics, Inc. (SER). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -339. 7% for Serina Therapeutics, Inc.. Over a 3-year CAGR, INMB leads at -48. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cassava Sciences, Inc.

(SAVA) is the more profitable company, earning 0. 0% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SAVA leads at 0. 0% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Serina Therapeutics, Inc.

(SER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). INmune Bio, Inc. (INMB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SER: -98. 2%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SER is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; INMB is a small-cap high-growth stock; SAVA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.